LLY

1,003.05

-0.18%↓

JNJ

245.77

-0.03%↓

ABBV

235.03

+0.78%↑

NVS

164.36

+0.67%↑

AZN

201.82

+0.8%↑

LLY

1,003.05

-0.18%↓

JNJ

245.77

-0.03%↓

ABBV

235.03

+0.78%↑

NVS

164.36

+0.67%↑

AZN

201.82

+0.8%↑

LLY

1,003.05

-0.18%↓

JNJ

245.77

-0.03%↓

ABBV

235.03

+0.78%↑

NVS

164.36

+0.67%↑

AZN

201.82

+0.8%↑

LLY

1,003.05

-0.18%↓

JNJ

245.77

-0.03%↓

ABBV

235.03

+0.78%↑

NVS

164.36

+0.67%↑

AZN

201.82

+0.8%↑

LLY

1,003.05

-0.18%↓

JNJ

245.77

-0.03%↓

ABBV

235.03

+0.78%↑

NVS

164.36

+0.67%↑

AZN

201.82

+0.8%↑

Home・Akciju saraksts・AnaptysBio Inc

AnaptysBio Inc

Atvērts

SektorsVeselības aprūpe

59.05 10.79

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

52.47

Max

61.03

Galvenie mērījumi
By Trading Economics
Ienākumi	54M 15M
Pārdošana	54M 76M
Peļņas marža	19.802
Darbinieki	136
EBITDA	57M 38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+54.8% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	511M 1.5B
Iepriekšējā atvēršanas cena	48.26
Iepriekšējā slēgšanas cena	59.05

Ziņu noskaņojums

By Acuity

54%

46%

280 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

19.25 / 21.135 Atbalsts un pretestība

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. marts 18:43 UTC

Galvenie ziņu notikumi

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026. g. 3. marts 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026. g. 3. marts 23:45 UTC

Tirgus saruna

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026. g. 3. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 3. marts 22:38 UTC

Galvenie ziņu notikumi

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026. g. 3. marts 22:16 UTC

Peļņas

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026. g. 3. marts 22:09 UTC

Peļņas

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026. g. 3. marts 22:06 UTC

Peļņas

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026. g. 3. marts 22:05 UTC

Peļņas

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026. g. 3. marts 22:03 UTC

Peļņas

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 3. marts 21:45 UTC

Galvenie ziņu notikumi

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026. g. 3. marts 21:37 UTC

Peļņas

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026. g. 3. marts 21:26 UTC

Galvenie ziņu notikumi

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026. g. 3. marts 20:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026. g. 3. marts 20:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026. g. 3. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold and Silver Drop as Energy Surges -- Market Talk

2026. g. 3. marts 18:43 UTC

Peļņas

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026. g. 3. marts 18:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026. g. 3. marts 18:14 UTC

Peļņas

How Long Can Anthropic Play Defense? -- WSJ

2026. g. 3. marts 17:41 UTC

Galvenie ziņu notikumi

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026. g. 3. marts 17:36 UTC

Galvenie ziņu notikumi

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026. g. 3. marts 17:28 UTC

Iegādes, apvienošanās, pārņemšana

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

54.8% augšup

Prognoze 12 mēnešiem

Vidējais 85 USD 54.8%

Augstākais 140 USD

Zemākais 56 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

280 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.